HR and breast cancer: Among the four breast cancer subtypes, HR+/HER2− subtype showed the highest 5-year BCSS rate (93.0%).HR+/HER2+ subtype showed a higher 5-year BCSS rate (90.0%) than HR−/HER2+ (84.9%) and HR−/HER2− subtypes (79.3%).